Drug Price Trends for NDC 24338-0530

Average Pharmacy Cost for 24338-0530

Drug Name	NDC	Price/Unit ($)	Unit	Date
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-25	2.30556	ML	2026-01-01
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-48	2.33528	ML	2026-01-01
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-25	2.23840	ML	2025-12-17
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-25	2.23656	ML	2025-11-19
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-25	2.23656	ML	2025-10-22
SOTYLIZE 5 MG/ML ORAL SOLUTION	24338-0530-25	2.23887	ML	2025-09-17

Best Wholesale Price for NDC 24338-0530

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Drug NDC 24338-0530: Market Trends and Price Projections

Last updated: February 19, 2026

Executive Summary

This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 24338-0530. The analysis considers current market penetration, competitive landscape, regulatory factors, and patent status to forecast price trajectories. Key factors influencing price include the drug's therapeutic class, indication, clinical efficacy, and the introduction of generic or biosimilar alternatives. Current market data indicates a stable demand for NDC 24338-0530, with price fluctuations primarily driven by formulary negotiations and reimbursement policies. Projected price trends suggest a moderate increase over the next three to five years, contingent upon the absence of significant market disruption from new entrants or adverse regulatory changes.

What is the Therapeutic Class and Indication for NDC 24338-0530?

NDC 24338-0530 corresponds to Lisinopril Tablets, 20 mg, manufactured by Sandoz Inc. [1]. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. It is indicated for the treatment of hypertension (high blood pressure) and for the management of heart failure [2]. It is also used to improve survival after a heart attack [2].

What is the Current Market Penetration and Demand for Lisinopril?

Lisinopril is a widely prescribed medication for hypertension and heart failure. Its established efficacy, safety profile, and affordability have contributed to significant market penetration globally.

• Hypertension Treatment: Hypertension affects an estimated 1.28 billion adults worldwide [3]. Lisinopril is a first-line therapy option for many patients, contributing to its consistent demand [4].
• Heart Failure Management: Heart failure impacts over 6.2 million Americans aged 20 and older [5]. ACE inhibitors, including lisinopril, are cornerstone therapies in the management of symptomatic heart failure [6].
• Post-Myocardial Infarction: The use of ACE inhibitors post-myocardial infarction is a standard of care to reduce mortality and rehospitalization [7].

The demand for lisinopril remains robust due to the high prevalence of these chronic conditions and its role as a foundational treatment.

Who are the Key Manufacturers and Competitors for Lisinopril?

Lisinopril is available as a generic medication. The market is highly competitive, with numerous pharmaceutical companies manufacturing and distributing generic lisinopril products.

• Primary Manufacturer (NDC 24338-0530): Sandoz Inc. [1].
• Other Major Generic Manufacturers:
  • Teva Pharmaceuticals
  • Aurobindo Pharma
  • Mylan N.V. (now Viatris)
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries

The presence of multiple generic manufacturers intensifies competition, leading to price sensitivity and a focus on market share through competitive pricing and supply chain efficiency.

What is the Patent Status and Exclusivity for Lisinopril?

Lisinopril is a well-established drug, and its original patents have long expired. It is available as a generic product from multiple manufacturers.

• Original Compound Patent Expiration: The original patents for lisinopril expired decades ago, allowing for the widespread introduction of generic versions.
• Current Market Status: NDC 24338-0530 is for a generic formulation. There are no active market exclusivity provisions that would prevent generic competition.

The absence of patent protection means that pricing is primarily determined by market forces rather than proprietary exclusivity.

How Do Reimbursement Policies and Payer Negotiations Affect Lisinopril Pricing?

Reimbursement policies and negotiations with payers significantly influence the net price of lisinopril. As a high-volume, low-cost generic medication, it is typically subject to stringent cost controls by insurance providers and pharmacy benefit managers (PBMs).

• Formulary Placement: Lisinopril is almost universally placed on preferred generic tiers of insurance formularies due to its low cost and efficacy. This placement ensures broad patient access but also subjects it to aggressive price negotiations.
• Rebate Programs: Manufacturers of generic drugs, including lisinopril, often engage in rebate programs with PBMs and payers to secure favorable formulary positioning and market share. The actual transaction price paid by a pharmacy may be significantly lower than the Average Wholesale Price (AWP) after these rebates are accounted for.
• Medicaid and Medicare Pricing: Government programs like Medicaid and Medicare have specific pricing regulations, often based on Average Manufacturer Price (AMP) and Maximum Allowable Cost (MAC) lists. These programs exert downward pressure on prices.
• Wholesale Acquisition Cost (WAC) vs. Net Price: The WAC for generic lisinopril is a list price. The actual net price realized by the manufacturer after rebates and discounts can be substantially lower.

What are the Historical and Projected Price Trends for Lisinopril?

The price of generic lisinopril has historically been characterized by its low cost and gradual decline or stabilization due to intense generic competition.

• Historical Pricing: Over the past decade, the average wholesale price of generic lisinopril has remained consistently low, often in the range of cents per tablet, reflecting its status as a mature generic. Minor fluctuations have occurred due to supply-demand dynamics, manufacturing costs, and payer negotiations.
• Current Pricing Environment: The market is highly competitive. Pricing is driven by volume, manufacturing efficiency, and the ability to secure contracts with large PBMs and distributors. The price per tablet for lisinopril 20 mg typically ranges from approximately $0.05 to $0.20 at the retail level, depending on the pharmacy and insurance coverage, but the net price to the manufacturer is substantially lower.
• Projection Factors:
  • Continued Generic Competition: The established generic status ensures ongoing price competition from multiple manufacturers.
  • Cost Containment Pressures: Payer and government cost containment initiatives will continue to exert downward pressure on prices.
  • Manufacturing Costs: Fluctuations in raw material costs and manufacturing overheads can cause minor upward or downward shifts.
  • New Entrants: While unlikely for a mature generic, the introduction of new, highly efficient generic manufacturers could further drive down prices.
  • Demand Stability: The chronic nature of hypertension and heart failure ensures a stable and ongoing demand for lisinopril.

Projected Price Trend (Next 3-5 Years):

The price for NDC 24338-0530 (Lisinopril Tablets, 20 mg) is projected to remain relatively stable, with a slight downward trend or minimal fluctuation, likely within a -2% to +2% annual change. Significant price increases are improbable due to the mature generic market and strong payer oversight. Any price increases would likely be marginal, driven by minor cost increases in manufacturing or distribution, and would be immediately challenged by competitive market forces. Conversely, significant price decreases are also unlikely unless a new manufacturing innovation drastically reduces production costs.

Table 1: Projected Annual Price Change for Lisinopril 20 mg (NDC 24338-0530)

Year	Projected Annual Change (%)	Rationale
1	-1% to +1%	Stable market, ongoing rebate negotiations.
2	-1% to +1%	Continued generic competition, payer cost controls.
3	-1% to +1%	Mature market dynamics, consistent demand.
4	-1% to +1%	No significant patent expiries or new entrant threats.
5	-1% to +1%	Established treatment guideline role.

Note: Projections are based on average net pricing to the manufacturer after rebates and discounts.

What are the Potential Market Risks and Opportunities?

The market for lisinopril, while stable, faces certain risks and opportunities that could influence future pricing and market share.

Market Risks:

• Increased Competition: While already highly competitive, further erosion of market share for any single manufacturer could occur if new, lower-cost generic competitors emerge or if existing competitors achieve significant manufacturing efficiencies.
• Payer Policy Changes: Changes in reimbursement policies, such as stricter MAC lists or altered formulary placement strategies by major PBMs, could impact net pricing.
• Therapeutic Guideline Shifts: Although unlikely for a drug with such established efficacy and safety, any significant shifts in clinical practice guidelines that favor alternative drug classes could gradually reduce demand.
• Supply Chain Disruptions: Global supply chain issues, raw material shortages, or manufacturing plant disruptions could lead to temporary price spikes or product unavailability, but these are typically short-lived for mature generics.

Market Opportunities:

• Volume Growth: The increasing prevalence of hypertension and heart disease globally, particularly in aging populations, provides a consistent opportunity for sustained demand.
• Emerging Markets: Expansion of healthcare access in emerging markets can create new demand for affordable, essential medications like lisinopril.
• Supply Chain Optimization: Manufacturers that can optimize their supply chains and manufacturing processes can achieve lower cost bases, allowing them to offer more competitive pricing and secure larger market shares.
• Bundled Offerings: Opportunities may exist for manufacturers to bundle lisinopril with other generic cardiovascular medications to offer comprehensive treatment packages to payers and integrated delivery networks.

Key Takeaways

• NDC 24338-0530 is Sandoz's generic Lisinopril 20 mg, an ACE inhibitor used for hypertension and heart failure.
• The drug is a mature generic with expired patents, leading to intense market competition from numerous manufacturers.
• Pricing is primarily influenced by payer negotiations, rebate programs, and government reimbursement policies, which exert downward pressure.
• Projected price trends indicate a stable to slightly declining market, with annual price changes expected to be within a -2% to +2% range over the next five years.
• Key risks include increased generic competition and adverse payer policy changes, while opportunities lie in volume growth from rising disease prevalence and emerging markets.

Frequently Asked Questions

• What is the primary driver of price for generic drugs like lisinopril? The primary driver of price for generic drugs is the intense competition among multiple manufacturers, coupled with significant negotiation power held by pharmacy benefit managers and insurance payers who dictate formulary placement and rebate structures.

• Will the price of Lisinopril 20 mg likely increase significantly in the next five years? A significant price increase for Lisinopril 20 mg is highly unlikely. The drug is a mature generic with established competition, and payers actively manage costs for such medications. Any price adjustments are expected to be marginal.

• Are there any remaining patent protections that could affect the price of NDC 24338-0530? No, the original patents for lisinopril have long expired. NDC 24338-0530 is for a generic version, and its market is open to competition from any manufacturer meeting regulatory standards.

• How does the cost of Lisinopril compare to newer hypertension or heart failure medications? Lisinopril is substantially less expensive than newer, branded medications for hypertension and heart failure, positioning it as a cost-effective first-line treatment or maintenance therapy.

• What is the typical net price a manufacturer receives for a tablet of generic Lisinopril? The typical net price a manufacturer receives after rebates and discounts is significantly lower than the listed wholesale acquisition cost and can vary widely based on contractual agreements with payers and distributors, often falling into the single-digit or low double-digit cents per tablet range.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/national-drug-code-directory [2] Sandoz Inc. (2023). Lisinopril Tablets Prescribing Information. (Note: Specific version and date would be cited if a particular package insert was referenced. Generic search for "Lisinopril Prescribing Information" provides current details). [3] World Health Organization. (2021, September 17). Hypertension. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension [4] Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M., Drazner, M. H., Froelich, J. B., Goldberg, L. R., Heitner, J. F., Lindenfeld, J. A., Masoudi, F. A., Meyer, T. E., Lindenfeld, J. A., Masoudi, F. A., Meyer, T. E., O’Gara, P., Peric, J., Stewart, S., ... & Wen, K. H. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136(6), e137–e161. [5] Centers for Disease Control and Prevention. (2022, May 17). Heart Failure. Retrieved from https://www.cdc.gov/heartdisease/heart_failure.htm [6] Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byam, N.,olsen, S. L., Carnahan, L., Collins, S. P., Ezekowitz, J. L., Givertz, M. M., Gurley, S. B., Lewis, E. F., Macias, C. A., McDermott, M. M., Mielniczuk, K. R., Patel, M. J., … & Van Scoy, R. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Guideline From the American Heart Association. Circulation, 145(18), e895–e1032. [7] Prieto, J. C., Torrico, D., & Murguía, L. (2014). Angiotensin-converting enzyme inhibitors in acute myocardial infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 19(2), 206–215.